Carl Zeiss Meditec AG (AFXd)

BATS Europe


	Symbol		Exchange		Currency
	AFXG		Xetra		EUR	Delayed
	AFXd		BATS Europe		EUR	Delayed
	CZMWY		OTC Markets		USD	Delayed
	0DHC		London		EUR	Real-time
	1AFX		Milan		EUR	Real-time
	AFXG		TradeGate		EUR	Delayed
	AFXG		Frankfurt		EUR	Delayed
	AFXG		Vienna		EUR	Real-time

Currency in EUR

58.60

0.00(0.00%)

Delayed Data27/11

Fair Value

Day's Range

57.68

58.60

52 wk Range

54.60

119.55

AFXd Income Statement

Featured here, the Income Statement (earnings report) for Carl Zeiss Meditec AG, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

30/09

2015

30/09

2016

30/09

2017

30/09

2018

30/09

2019

30/09

2020

30/09

2021

30/09

2022

30/09

2023

30/09

Total Revenues

1,459.32

1,335.45

1,646.79

1,902.84

2,089.3

Total Revenues Growth

+13.93%

-8.49%

+23.31%

+15.55%

+9.8%

Cost Of Revenues

627.44

589.94

679.57

775.24

883.54

Gross Profit

831.88

745.52

967.21

1,127.6

1,205.77

Gross Profit Growth

+17.1%

-10.38%

+29.74%

+16.58%

+6.93%

Gross Profit Margin %

57%

55.83%

58.73%

59.26%

57.71%

Other Operating Expenses, Total

567.78

568.59

596.83

729.92

852.1

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+10.49%	+0.14%	+4.97%	+22.3%	+16.74%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	173.31	218.8	232.07	291.37	349.28
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	394.47	349.78	364.77	438.55	502.82
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

264.1

176.93

370.38

397.68

353.67

Operating Income Growth

+34.38%

-33.01%

+109.34%

+7.37%

-11.07%

EBIT Margin %

18.1%

13.25%

22.49%

20.9%

16.93%

Net Interest Expenses

-5.85

-25.81

-7.02

4.15

12.86

Net Interest Expenses Growth

-444.19%

-341.18%

+72.82%

+159.16%

+209.83%

Interest Expense, Total

-7.65

-27.27

-8.58

-9.1

-15.25

Interest And Investment Income

1.8

1.46

1.56

13.25

28.11

Other Non Operating Expenses, Total

-28.39

4.47

-25.02

-50.79

35.46

EBT, Excl. Unusual Items

229.86

155.59

338.35

351.04

401.98

Gain (Loss) On Sale Of Assets

-

-

2.45

-

-

Other Unusual Items, Total

-

23.13

-1.84

52.45

10.88

EBT, Incl. Unusual Items

229.86

178.72

339.05

403.49

412.56

EBT, Incl. Unusual Items Growth

+28.28%

-22.25%

+89.71%

+19.01%

+2.25%

EBT, Incl. Unusual Items Margin

15.75%

13.38%

20.59%

21.2%

19.75%

Income Tax Expense

69.28

55.3

101.53

107.58

120.56

Net Income to Company

160.58

123.42

237.52

295.91

292.01

Minority Interest

-0.82

-1.04

-1.24

-2

-1.61

Net Income

159.76

122.39

236.28

293.91

290.4

Net Income Growth

+26.33%

-23.39%

+93.06%

+24.39%

-1.2%

Net Income Margin %

10.95%

9.16%

14.35%

15.45%

13.9%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

159.76

122.39

236.28

293.91

290.4

Basic EPS - Continuing Operations

1.79

1.37

2.64

3.29

3.25

Basic EPS - Continuing Operations Growth

+26.33%

-23.39%

+93.06%

+24.39%

-1.2%

Diluted EPS - Continuing Operations

1.79

1.37

2.64

3.29

3.25

Diluted EPS - Continuing Operations Growth

+26.33%

-23.39%

+93.06%

+24.39%

-1.2%

Basic Weighted Average Shares Outstanding

89.44

89.44

89.44

89.44

89.44

Diluted Weighted Average Shares Outstanding

89.44

89.44

89.44

89.44

89.44

Dividend Per Share

0.65

0.5

0.9

1.1

1.1

Dividend Per Share Growth

+18.18%

-23.08%

+80%

+22.22%

0%

EBITDA

284.04

200.04

388.94

418.29

375.31

EBITDA Growth

+30.51%

-29.57%

+94.43%

+7.55%

-10.27%

EBITDA Margin %